## ORION CORPORATION B

ISIN: FI0009014377 WKN: ORNBV Asset Class: Stock



### **Company Profile**

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

### Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	825,300,000		878,700,000		690,300,000	
Common stock capital		92,200,000		92,200,000		92,200,000
Fixed assets	621,100,000		624,900,000		423,700,000	
Equity capital of a company		890,100,000		908,100,000		747,900,000
Cash and cash equivalents	106,700,000		332,600,000		216,700,000	
Accrued liabilities		4,600,000		3,600,000		5,300,000
Other assets	-		-		-	
Current liabilities		264,800,000		275,300,000		209,100,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		291,500,000		320,200,000		157,000,000
Different income		-		-		-
Other liabilities		76,300,000		77,700,000		13,000,000
Total assets	1,446,400,000	1,446,400,000	1,503,600,000	1,503,600,000	1,114,000,000	1,114,000,000

# **Balance notes**

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	3,632	3,527	3,355
Equity ratio	61.54%	60.40%	67.14%
Debt-equity ratio	62.50%	65.58%	48.95%

#### **Others**

	2023	2022	2021
Tax Expense Rate	20.26%	20.62%	20.02%

# **ORION CORPORATION B**

ISIN: FI0009014377 WKN: ORNBV Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	1,191,300,000	1,333,300,000	1,038,900,000
Net income	216,800,000	349,500,000	193,800,000
EBIT	274,700,000	441,100,000	243,500,000
Operating income before taxes	271,900,000	440,300,000	242,300,000
Cash Flow	119,000,000	434,400,000	215,700,000
Net interest income	-2,800,000	-800,000	-1,200,000
Research and development expenses	122,300,000	131,100,000	114,000,000
Income taxes	55,100,000	90,800,000	48,500,000
Result from investments in subsidaries, associates and other	-	0	-
Revenues per employee	328,001	378,027	309,657

<b>Board of Directors</b>	
Veli-Matti Johannes Mattila	Chairman of Supervisory Board
Ari Tapio Lehtoranta	Member of Supervisory Board
Hilpi Rautelin	Member of Supervisory Board
Eija Ronkainen	Member of Supervisory Board
Henrik Stenqvist	Member of Supervisory Board
Karen Sörensen	Member of Supervisory Board
Kari Jussi Aho	Member of Supervisory Board
Maziar Mike Doustdar	Member of Supervisory Board

Members of Management Board		
Liisa Hurme	Chairman of Managing Board	
Hao Pan	Member of Executive Committee	
Jani Korhonen	Member of Executive Committee	
Jari Karlson	Member of Executive Committee	
Juhani Kankaanpää	Member of Executive Committee	
Julia Macharey	Member of Executive Committee	
Niclas Lindstedt	Member of Executive Committee	
Olli Huotari	Member of Executive Committee	
Outi Vaarala	Member of Executive Committee	
Satu Ahomäki	Member of Executive Committee	
Virve Laitinen	Member of Executive Committee	